Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene study aims to personalize common heart drug

NCT ID NCT03051282

Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how genetic differences affect the activation of enalapril, a common blood pressure medication. Researchers gave 21 healthy volunteers enalapril for a week and measured drug levels in their blood. The goal was to see if a specific gene variant (G143E) changes how the body processes the drug, which could lead to more personalized dosing in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
enalapril
What this could lead to
If successful, this could help doctors personalize ACE inhibitor dosing based on a person's genetics, improving effectiveness and reducing side effects.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. Results may not translate to real-world treatment or account for other factors affecting drug response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

21 people

The number who actually took part.

Started

Apr 2017

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Subjects must be male and female (50:50) between the ages of 18-55 years * Females must have a negative urine pregnancy test prior to the study * All subjects must have no clinically significant diseases or clinically significant abnormal laboratory values as assessed during the screening medical history, nursing assessment, and laboratory evaluations * Informed consent must be signed by the eligible subject prior to the initiation of any study procedures Exclusion Criteria: * The presence of a known medical condition that would preclude the use of enalapril * The presence of any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion. * A positive urine pregnancy test in the MCRU prior to the study * No subjects weighing under 50 kg will be selected * The lack of use of acceptable methods of birth control unless abstinent * Subjects who regularly take medications, vitamins, herbal supplements * The use of any illicit drugs or habitual consumption of large quantities of ethanol (\>3 drinks/day) * The consumption of grapefruit or grapefruit juice a week prior to, and during the study * Asians will not be included in the study as the CES1 SNP G143E is absent in this population * Subjects hypersensitive to enalapril * Subject with a history of angioedema * Smokers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy volunteers

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.